ArticleFrontiers in cellular and infection microbiology2026
Endothelial glycocalyx injury in bacterial bloodstream infection: biological determinants and association with host response aberrations.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Damage to the endothelial glycocalyx plays a key role in the pathogenesis of sepsis. Syndecan-1 is a widely used biomarker of glycocalyx degradation. The objectives of this study were (1) to determine whether the pathogen type is correlated with differences in glycocalyx disruption in critically ill patients with bacterial bloodstream infection (BSI) and (2) to assess the association of plasma syndecan-1 levels with host response changes implicated in the pathogenesis of sepsis. Methods: We measured 24 plasma biomarkers reflective of key pathophysiological domains and whole-blood transcriptomes in intensive care unit (ICU) patients with bacterial BSI. Plasma syndecan-1 was used as biomarker of glycocalyx degradation. Results: In 188 ICU patients, the most common pathogens were Discussion: In ICU patients with BSI, glycocalyx disruption as measured by plasma syndecan-1 is associated with poor clinical outcomes and a variety of host response aberrations. Glycocalyx disruption in BSI appears to relate more strongly to disease severity than to the causative pathogen category.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.